Assessing Platelet Reactivity with Point-of care Systems Christian Valina Herz-Zentrum Bad Krozingen Oral Antiplatelet Therapy After PCI: Optimizing Outcomes.

Slides:



Advertisements
Similar presentations
Monitoring platelet function using the Multiplate® analyzer
Advertisements

Thromboelastography as an Adjunct Tool to Assess Coagulation Disturbances in Isolated Traumatic Brain Injury Patients Asaph Nini MD 1, David Livingstone.
Basic Clinician Training
Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.
Basic Clinician Training Module 7 PlateletMapping™ PlateletMapping™ Assays.
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ® )
Assessment of the best Loading dose of clopidogrel to Blunt platelet activation, Inflammation and Ongoing Necrosis ALBION.
OUTLINE: I.Historical Perspective. A. Development of Thromboelastography. B. The expansion and transition from Cardiac Surgery to Trauma. II.Traditional.
Platelet Function Testing
General Approach in Investigation of Haemostasis Platelets aggregation.
Journal Club Precision and Reliability of 5 Platelet Function Tests in Healthy Volunteers and Donors on Daily Antiplatelet Agent Therapy B.S. Karon, N.V.
General Approach in Investigation of Haemostasis
T: Dr Lelanie Pretorius MBChB, MMed (Haemat), PG Dip (Transfusion Medicine) Dept of Haematology and Cell Biology.
MLAB Coagulation Keri Brophy-Martinez
Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.
Brar et al, JACC 2011 Impact of Platelet Reactivity When On-treatment With Clopidogrel on Mortality, MI or Stent Thrombosis After PCI Impact of Platelet.
Coagulation Automation Joanna Ellis, MLS (ASCP) Keri Brophy-Martinez, MHA/ED (ACHE), MT(ASCP)
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD.
Basic Clinician Training Module 3
Dose- and time-dependent antiplatelet effects of aspirin Christina Perneby, N. Håkan Wallén, Cathy Rooney, Desmond Fitzgerald, Paul Hjemdahl Published.
Mrs. Ibtisam H. Alaswad Mr. Mohammed A. Jaber
Basic Clinician Training Module 2
Measurement of Clopidogrel Resistance by ADP-Inhibition Does Not Reflect the Benefit of Clopidogrel on Overall Thrombotic Status Dr Diana A Gorog Consultant.
Point of Care Platelet Function Testing – Is There Still Value?
Dr. S. Parthasarathy MD., DA., DNB, MD (Acu), Dip. Diab. DCA, Dip. Software statistics PhD (physio) Mahatma Gandhi medical college and research institute,
Post-PCI/MI Thrombotic Events – A Plateletcentric Problem!!!!
Daniel I. Simon, M.D. Associate Director, Interventional Cardiology Brigham and Women’s Hospital Associate Professor of Medicine Harvard Medical School.
Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:
(The CLEAR PLATELETS-2 Study) Bivalirudin With and Without Eptifibatide for Elective Stenting: A Pharmacodynamic Study of Platelet Reactivity in Relation.
Proton Pump Inhibitor (PPI) Studies
Aspirin Resistance. Clinical Questions How do we define aspirin resistance? Is this concept clinically relevant? Why aren’t we testing for it?
Clinical Trial Results. org Increased Risk in Patients with High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary.
A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Marie.
Laboratory Testing in Coagulation Coagulation Keri Brophy-Martinez.
Intrinsic pathway Extrinsic pathway Common pathway The extrinsic pathway was required the addition of an exogenous trigger (originally provided by tissue.
Measurement of Antiplatelet Therapeutic Efficacy Bonnie H. Weiner MD MSEC MBA FSCAI FACC FAHA Professor of Medicine Director, Interventional Cardiology.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.
Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.
Rossella Marcucci, MD; Anna Maria Gori, BS; Rita Paniccia, BS; Betti Giusti, BS; Serafina Valente, MD; Cristina Giglioli, MD; Piergiovanni Buonamici, MD;
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Elevated Plasma Fibrinogen Rather Than Residual.
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: Platelet Biology and Response to Antiplatelet Therapy.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impaired Responsiveness to the Platelet P2Y 12 Receptor.
What Should we Learn from the POPular Study?
Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock – a.
PhenGene P2Y12 Test.
Thrombelastograph® (TEG®) Coagulation Analyzer
Effect of Aspirin Dose on Platelet Reactivity in Diabetic Patients Paul A. Gurbel, MD Director, Sinai Center for Thrombosis Research Sinai Hospital.
The GRAVITAS trial Matthew J. Price MD, FACC, FSCAI
Platelet Function Testing: Is GRAVITAS the Last Word?
Platelet Function Testing: Which one Should we Perform and
Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,
Blood Management Anesthesiology Clinics
Anti-Coagulants Physical Process of Clotting
Activated Partial Thromboplastin Time (aPTT)
Vessel wall BAMBI contributes to hemostasis and thrombus stability
How I treat patients with massive hemorrhage
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
Anti-Coagulants Physical Process of Clotting
Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action  D.A. Payne, FRCS(Ed)a,
ASA Resistance and Clinical Outcomes
Severe bleeding as a result of platelet inhibition caused by floxacillin treatment for endocarditis  Juliane Rau, MD, Mark Simon, MD, Michael Sander,
Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis by Manasa K. Nayak, Nirav Dhanesha,
TEG platelet map tracing.
Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thrombelastography®
The Use of Global Assays to Monitor Emicizumab Prophylactic Therapy in Patients with Hemophilia A with Inhibitors Mid-Atlantic Region III HTCs Annual.
Perioperative monitoring of platelet function in paediatric cardiac surgery by thromboelastometry, or platelet aggregometry?†   B.S. Romlin, F Söderlund,
Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem®): an in vitro study  M Mittermayr, J.
Treatment of dogs with celecoxib interferes with the effect of low-dose aspirin on ex vivo platelet aggregation. Treatment of dogs with celecoxib interferes.
Individual test results of VerifyNow (A), the Multiplate (B), and LTA (C). Individual test results of VerifyNow (A), the Multiplate (B), and LTA (C). The.
Coagulation monitoring and management of anticoagulation during cardiac assist device support  Dietmar Fries, MD, Petra Innerhofer, MD, Werner Streif,
Presentation transcript:

Assessing Platelet Reactivity with Point-of care Systems Christian Valina Herz-Zentrum Bad Krozingen Oral Antiplatelet Therapy After PCI: Optimizing Outcomes in Clinical Practice

Assessing Platelet Reactivity with Point-of care Systems Platelet-function tests What kind of POC-tests are available? Differences in test results

Assessing Platelet Reactivity with Point-of care Systems Platelet-function tests What kind of POC-tests are available? Differences in test results

Platelet-function tests Test principleTests Cessation of bleeding from a standardized wound in vivo Bleeding time AggregometryLight transmission aggregometry (LTA) Multiplate ® WBA VerifyNow ® Platelet counting method (e.g. Ichor-plateletworks ® ) Thrombovision T ® guide Flow cytometryDetection of activation markers ex vivo Ex vivo stimulation and detection of activation markers VASP phosphorylation Shear dependent platelet function within whole blood PFA-100 ® IMPACT ® -CPA Placor PRT-7000 ® Global haemostasis testsThrombelastography (TEG ® ) Thrombelastometry (ROTEM ® ) Haemostasis Analysis System ® Thromboxane measurementsSerum thromboxane B 2 Harrison, Hämostaseologie 2009; 29: 25

Platelet function testing: Some Problems No definitive screening test Methodological variability within each technique Labor intensive Costly Time consuming Requirement of fair degree of expertise and experience to perform and interpret Often requirement of additional expensive specialist tests Lack of a standardized definition of suboptimal platelet response

Assessing Platelet Reactivity with Point-of care Systems Platelet-function tests What kind of POC-Devices are available? Differences in test results

Point-of-care-testing: What should they can? Bed-side testing No sample preparation Ready-to-use Easy to use Rapid read out Short Turn-around-Time (TAT)

Point-of-care-testing: Test Principles POC-SystemTest principle VerifyNow ® Multiplate ® WBA Aggregometry PFA-100 ® IMPACT ® -CPA Placor PRT-7000 ® Shear dependent platelet function within whole blood Thrombelastography (TEG ® ) Thrombelastometry (ROTEM ® ) Haemostasis Analysis System ® Global haemostasis tests, monitoring of rate and quality of clot formation Ichor-Plateletworks ® Platelet counting pre- and postactivation HemoStatus ® Platelet procoagulant activity

VerifyNow ® Whole blood (citrated) without further sample preparation No need for time-consuming centrifugation steps Turbidimetric based optical detection of platelet aggregation stimulated by a specific agonist Disposable cartridges contain fibrinogen-coated beads and platelet activator (3 cartridges available: aspirin, P2Y 12, GPIIb/IIIa)

VerifyNow ® Technology

Results Screen VerifyNow P2Y12 Assay PRU result is ‘P2Y12-mediated platelet aggregation’ via adenosine diphosphate (ADP) pathway VerifyNow ® P2Y12 results can then be reported as % platelet inhibition Base result is ‘Maximal platelet aggregation’ via Thrombin Receptor Activating Peptide (TRAP) pathway which is independent of aspirin and clopidogrel Print

Correlation of VerifyNow ® with LTA

Multiplate ® system (“multiple platelet function analyzer”) Whole blood (hirudinized) Multiple electrodes in the disposable test cell (4 electrodes form 2 independent sensor units), multiple channels of the instrument (5). Detects the effects of the platelet inhibitors Aspirin ®, clopidogrel and GpIIb/IIIa antagonists, and also the newer direct ADP receptor antagonists. No luminescence available, low shear system, does not simulate normal haemostasis. Continuously records platelet aggregation. Increase of impedance by the attachment of Platelets onto the Multiplate ® sensors is transformed to arbitrary aggregation units (AU) and plotted against time. Three parameters: –Area under the aggregation curve (AUC). –Aggregation is the height of the curve. V –Velocity is the maximum slope of the curve.

Platelet Function Assay 100 (PFA-100) Analyzer device and disposable cartridge Whole blood Measurment of time to occlusion of aperture in mebrane coated with collagen/ADP or collagen/epinephrin under high shear stress conditions Cannot distinguish thienopyridene effect 160µm - 40mbar Flow direction

Thromboelastography (TEG) Haemoscope's TEG® 5000 system Small sample of blood (typically 0.36 ml), is placed into a gently rotating cuvette (imitates venous flow and activate coagulation) => Sensor shaft inserted into the sample => a clot forms between the cup and the sensor. Speed and strength of clot formation is measured. Patterns of changes in strength and elasticity in the clot provide information. Four values that represent clot formation are determined by this test: –the R value (or reaction time): represents the speed of clot formation –the K value: end or R until the clot reaches 20mm –the angle and –the MA (maximum amplitude). clot strength Coagulation Index (CI) (or overall assessment of coagulability).

Assessing Platelet Reactivity with Point-of care Systems Platelet-function tests: Advantages of POC-Systems Platelet-function tests: What kind of POC-tests are available? Differences in test results

Differences in test results: Are they measuring the same? Low shear systems (e.g. Multiplate) does not simulate normal haemostasis Different stimulation reagents and dosages Is „baseline aggregation“ really „baseline“? „Units“: –% platelet inhibition or P2Y12 reaction units (VerifyNow) –Arbitrary aggregation units (Multiplate) –Closure time (PFA-100) –Maximum aggregation, residual aggregation, … (LTA) –Platelet reacitivity index (VASP-P) Cut-off values

Assessing Platelet Reactivity with Point-of care Systems Platelet-function tests: Advantages of POC-Systems Platelet-function tests: What kind of POC-tests are available? Differences in test results Cut-off values

VerifyNow: Cut off levels for „low response“ Trenk, 2008; TRIGGER(enrolling)> 208 PRU Godino, 2009> 213 PRU Price et al., 2008≥ 235 PRU ARMYDA-PRO, GRAVITAS (enrolling)≥ 240 PRU Paniccia et al., 2007 ≥ 264 PRU

Assessment of On-Clopidogrel Platelet Reactivity by LTA and VerifyNow 17.6 ± 16.2 % n= ± 90.5 n=307 LTA VerifyNow

VerifyNow ® PRU n=307 r 2 =0.441 Assessment of On-Clopidogrel Platelet Reactivity Correlation Between LTA and VerifyNow

AUC: Sensitivity for PRU 208: 0.53 Specificity for PRU 208: 0.88 Assessment of On-Clopidogrel Platelet Reactivity LTA versus VerifyNow by ROC Analysis

Cut off levels for „low response“ LTA:> 62% (Angiolillo, max. aggregation, ROC) TEG:> 50% (5mM ADP) >70% (10mM, ADP) VASP platelet reactivity index:>48% …..